• 1
    Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 7107.
  • 2
    El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5: 1726.
  • 3
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303: 23541.
  • 4
    El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100: 124350.
    Direct Link:
  • 5
    Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199211.
  • 6
    El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 2008; 53: 230712.
  • 7
    Nocon M, Labenz J, Jaspersen D, et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol 2007; 22: 172831.
  • 8
    Blondeau K, Boecxstaens V, Van Oudenhove L, et al. Increasing body weight enhances prevalence and proximal extent of reflux in GERD patients ‘on’ and ‘off’ PPI therapy. Neurogastroenterol Motil 2011; 23: 724e327.
  • 9
    Fornari F, Callegari-Jacques SM, Dantas RO, et al. Obese patients have stronger peristalsis and increased acid exposure in the esophagus. Dig Dis Sci 2011; 56: 14206.
  • 10
    de Vries DR, van Herwaarden MA, Smout AJ, et al. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol 2008; 103: 134954.
    Direct Link:
  • 11
    Ayazi S, Hagen JA, Chan LS, et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. J Gastrointest Surg 2009; 13: 14407.
  • 12
    Kuper MA, Kramer KM, Kirschniak A, et al. Dysfunction of the lower esophageal sphincter and dysmotility of the tubular esophagus in morbidly obese patients. Obes Surg 2009; 19: 11439.
  • 13
    Schneider JH, Kuper M, Konigsrainer A, et al. Transient lower esophageal sphincter relaxation in morbid obesity. Obes Surg 2009; 19: 595600.
  • 14
    Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007; 132: 8839.
  • 15
    El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure.Gut 2007; 56: 74955.
  • 16
    Fletcher J, Derakhshan MH, Jones GR, et al. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut 2011; 60: 4428.
  • 17
    Heading RC, Monnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011; 11: 52.
  • 18
    Sheu BS, Cheng HC, Chang WL, et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007; 102: 238794.
    Direct Link:
  • 19
    Sheu BS, Chang WL, Cheng HC, et al. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. Am J Gastroenterol 2008; 103: 220914.
    Direct Link:
  • 20
    Pace F, Coudsy B, DeLemos B, et al. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. Eur J Gastroenterol Hepatol 2011; 23: 84551.
  • 21
    Labenz J, Armstrong D, Zetterstrand S, et al. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis–results from the EXPO study. Aliment Pharmacol Ther 2009; 29: 95966.
  • 22
    Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24: 3716.
  • 23
    Carpiuc KT, Mody R, Perez MC, et al. Assessing the impact of body mass index (BMI) on the efficacy of proton pump inhibitors (PPIs) in GERD: a review of the literature. Am J Gastroenterol 2011; 106: S413.
  • 24
    Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009; 29: 126172.
  • 25
    Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 73141.
  • 26
    Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Ther 2005; 22: 7994.
  • 27
    Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012; 61: 5016.
  • 28
    Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011; 33: 21324.
  • 29
    Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011; 17: 38794.
  • 30
    Labenz J, Armstrong D, Zetterstrand S, et al. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis–results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther 2009; 29: 116571.
  • 31
    Jacobson BC. Body mass index and the efficacy of acid-mediating agents for GERD. Dig Dis Sci 2008; 53: 23137.
  • 32
    Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009; 25: 62738.
  • 33
    Fass R, Quan SF, O'Connor GT, et al. Predictors of heartburn during sleep in a large prospective cohort study. Chest 2005; 127: 165866.
  • 34
    Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011; 106: 42131.
  • 35
    Ribolsi M, Emerenziani S, Petitti T, et al. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. Dig Liver Dis 2012; 44: 54954.
  • 36
    Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20: 818.